Does an initial strategy of catheter ablation reduce a composite primary end-point event in patients with ischemic cardiomyopathy and ventricular tachycardia compared to antiarrhythmic drug therapy?
In patients with ischemic cardiomyopathy and ventricular tachycardia, an initial strategy of catheter ablation reduces the risk of adverse composite outcomes compared to antiarrhythmic drug therapy.
Among patients with ischemic cardiomyopathy and ventricular tachycardia, an initial strategy of catheter ablation led to a lower risk of a composite primary end-point event than antiarrhythmic drug therapy. (Funded by the Canadian Institutes of Health Research and others; VANISH2 ClinicalTrials.gov number, NCT02830360.).
Sapp et al. (Sat,) studied this question.